Frequently Asked Questions and Answers

A: Please email gstt.a-star@nhs.net and request for a feasibility form to complete and return to us. We will begin the process once the feasibility has been approved.

A: The current recruitment and study end date is 31-12-2027 

Medication start date is used to create a visit schedule. You can use the visit calculator template. 

A: Please email Becky directly, at  rebecca.carroll16@nhs.net, alongside the staff members email address, the updated site delegation log, relevant training certificates, and CV and GCP, to request this access.

A: Please email Becky directly, at rebecca.carroll16@nhs.net, to reinstate your access.  

A: Yes. Re-consent them with the adult PIS–ICF. Record the treatment-change visit as “baseline 2” and recalculate visits from the dupilumab start date. No new participant number is needed 

A: Yes. Please record it as a separate treatment course, but it does not require a Baseline 2. 

A: Yes. It is absolutely fine to call the patient first to check their interest before sending the PIS. 

A: Remote consent can be done in two ways: 

1. Email: Send the current PIS–ICF (v2, 01-FEB-2019) for the patient to sign electronically or scan/hand-sign and email back. One copy is enough for an adult; children need 1 parent/guardian form + 1 assent form. 

1. Post: Send the PIS–ICF via pre-paid postal envelope for return. 

A: Please record the visit when the decision to switch treatment was made, or when you were notified of the switch, as “Baseline 2/3/4…” (depending on the sequence). Each new baseline represents a regular follow-up visit that marks the start of a new treatment phase. This will reset the follow-up schedule, with the date the new treatment begins considered Day 0. The next follow-up should then occur 4 ± 2 weeks after Day 0, in line with the protocol’s schedule of events.